Photo of Matthew G. Oser,  MD, PhD

Matthew G. Oser, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 582-8668


moser@partners.org

Matthew G. Oser, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Instructor, Medicine, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

The goal of my research is to identify new therapeutic targets in small cell lung cancer (SCLC) with the ultimate goal of bringing novel therapies to the clinic for SCLC patients. My focus is to use Cas9/CRISPR screening approaches to identify novel candidate therapeutic targets in SCLC that are a consequence of pRB loss, NOTCH inactivation, and dependencies that alter SCLCs neuroendocrine differentiation state. I then study these new candidate target genes in vivo using a novel immunocompetent genetically-engineered mouse model (GEMM) of SCLC that I developed using CRISPR.

Publications

Powered by Harvard Catalyst
  • Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG. Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. 2018. PubMed
  • Oser MG, J√§nne PA. Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver. Clin Cancer Res 2018. PubMed
  • Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015; 16:e165-72. PubMed